7490. Pirenoxine
Nomenclature
CAS number: 1043-21-6
1-Hydroxy-5-oxo-5H-pyrido[3,2-a]phenoxazine-3-carboxylic
acid; 1-hydroxy-5H-pyrido[3,2-a]phenoxazin-5-one-3-carboxylic
acid; 1-hydroxy-3-carboxy-5H-pyrido[3,2-a]phenoxazin-5-one; pirfenoxone; Catalin (Senju). C16H8N2O5; mol wt 308.25.
C 62.34%, H 2.62%, N 9.09%, O 25.95%.
Description and references
Prepn: S. Ogino, JP 59 2227, C.A. 54, 11058i (1960); S. Ishii, JP 61 1782, C.A. 55, 21494e (1961) (1959, 1961 both to Chizu Drug); of the sodium salt: S. Ishii, K. Ogata, JP 73 2672 (1973 to Senju), C.A. 80, 6959t (1974). Pharmacological studies: F. Ikemoto et al., Oyo Yakuri 8, 937 (1974), C.A. 83, 71663t (1975). Toxicological studies: eidem, ibid. 911, 923, C.A. 82, 51617g, 68262k (1975). Influence on carbohydrate metabolism in the lens: I. Korte et al., Ophthalmic Res. 7, 282 (1975). Effect on NADH, NADPH: eidem, ibid. 440. Effect on senile cataracts: T. Murata, Folia Ophthalmol. Jpn. 31, 1217 (1980). Clinical trial in treatment of cataracts: S. K. Angra et al., Indian J. Ophthalmol. 31, 5 (1983).
Properties
Orange-yellow powder, mp 247-248° (dec).Derivative
Sodium salt.Nomenclature
CAS number: 51410-30-1
Clarvisan (Allergan). C16H7N2NaO5; mol wt 330.23.
C 58.19%, H 2.14%, N 8.48%, Na 6.96%, O 24.22%.
Properties
Very sol in water. LD50 in mice (mg/kg): >10000 orally; >5000 s.c.; 2120-2250 i.p.; LD50 i.p. in rats (mg/kg): 2400 (males); 1460 (females) (Ikemoto).Therapeutic Category
Treatment of cataracts.